The FDA has approved Boehringer Ingelheim’s Spevigo (spesolimab) for generalized pustular psoriasis (GPP) flares in adults, making it the first drug approved for this indication.

AstraZeneca’s blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalization and death in people with all types of heart failure, according to study data released on Saturday, opening the door to a substantial increase in patients who could benefit.

Western nations are working to lessen dependence on China as a supplier for ingredients and goods of all kinds, and China’s economy slowed significantly as a consequence of COVID-19 lockdowns, yet its biopharma sector appears strong. That’s because biotech is designated as a strategic emerging industry.

Three European biopharma firms are coming together to create one company with a mission to combat antimicrobial resistance (AMR). The new company, Aurobac Therapeutics SAS, was founded by Germany’s Boehringer Ingelheim and Evotec SE, along with France’s bioMérieux.

Protein degradation continues to be a hot area of interest for companies. Weeks after Bristol-Myers Squibb and Evotec forged a $5 billion collaboration expansion to develop molecular glue degraders, Merck KGaA and Austria’s Proxygen have struck a similar deal valued at $554 million.